Our advantage

Diagnostic reagents


Relying on the static nucleic acid preparation technology platform, the company has developed clinical application hepatitis B and C virus nucleic acid quantitative detection kits, and obtained the registration certificate of the General Administration of Drug Administration, and gradually promoted the use to hospitals at all levels.



Expert team


The company cooperates with many domestic PCR industry experts and has strong research and development strength. Through the static nucleic acid preparation technology platform, it can quickly realize the nucleic acid extraction of various pathogens and achieve accurate quantification of pathogens.




Since its establishment in 2015, the company has successively passed the audit of the CFDA and ISO13485 quality management system certification, obtained multiple three types of registration certificates, and obtained multiple invention patents.